logo RPQure v6 flattened v2

logo RPQure banner 2

group 2020 spring

Move from NIN to LUMC

The research team RPQure Neuromedical Genetics recently moved from the Netherlands Institute for Neuroscience (NIN) to the Leiden University Medical Center (LUMC) Department of Ophthalmology. Future clinical gene therapy studies for Retinitis Pigmentosa (RP) and Leber congenital amaurosis (LCA) patients with mutations in the CRB1 gene will be performed at the LUMC Department of Ophthalmology in the Netherlands.

News on AMD drug

Roche has announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug for geographic atrophy (GA), the advanced form of age-related macular degeneration (AMD).

Read more: News on AMD drug